Leukaemia (acute) Cancer Leukaemia
Conditions
Interventions
Four randomised comparisons:
At diagnosis:
1. S-DAT versus H-DAT
2. All-trans-retinoic acid (ATRA) versus not (except for acute promyelocytic leukaemia (APL) patients who will receive ATRA)
After
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Have one of the forms of AML 2. Are considered suitable for intensive chemotherapy 3. Are normally under the age of 60 years, but can be older as long as intensive therapy is considered suitable 4. Have given written informed consent
Exclusion criteria
Exclusion criteria: Added as of 07/03/2007: 1. Previously received any treatment for APL 2. Other forms of AML (including CML in promyelocytic blast crisis) 3. Another concurrent active malignancy 4. Pregnant or consider the possibility of becoming pregnant during the course of treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added as of 07/03/2007: Haemorrhagic complications, induction deaths, remission rate, remission duration, overall survival and the role of ATRA in correcting the coagulopathy associated with APL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed